4-Propyltriazin-5-amine

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 三嗪类
• 英文名称: 4-Propyltriazin-5-amine
• 英文别名: 4-propyltriazin-5-amine
• 化学式: C₆H₁₀N₄
• 分子量: 138.17
• InChiKey: XURKVWCFXAKJTH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.2
• 重原子数：
  10
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  64.7
• 氢给体数：
  1
• 氢受体数：
  4

文献信息

• NOVEL a4B7 PEPTIDE MONOMER AND DIMER ANTAGONISTS
  申请人：Protagonist Therapeutics, Inc.

  公开号：US20160152664A1

  公开（公告）日：2016-06-02

  The invention relates to peptide dimer compounds and peptide monomer compounds that potently inhibit binding of α4β7 to the mucosal addressin cell adhesion molecule (MAdCAM) in vivo, possess high selectivity against α4β1 binding, and have high stability under gastrointestinal conditions.

  本发明涉及一种肽二聚体化合物和肽单体化合物，它们在体内强烈抑制α4β7与黏膜地址素细胞粘附分子（MAdCAM）的结合，对α4β1结合具有高度选择性，并在胃肠道条件下具有高稳定性。
• Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases
  申请人：Protagonist Therapeutics, Inc.

  公开号：US10023614B2

  公开（公告）日：2018-07-17

  Peptide inhibitors of the interleukin-23 receptor, and related compositions and methods of using these peptide inhibitors to treat or prevent a variety of diseases and disorders, including inflammatory bowel disease, are disclosed.

  本研究公开了白细胞介素-23 受体的多肽抑制剂，以及使用这些多肽抑制剂治疗或预防包括炎症性肠病在内的多种疾病和失调的相关组合物和方法。
• α4β7 thioether peptide dimer antagonists
  申请人：Protagonist Therapeutics, Inc.

  公开号：US10059744B2

  公开（公告）日：2018-08-28

  The invention relates to thioether monomer and dimer peptide molecules which inhibit binding of α4β7 to the mucosal addressing cell adhesion molecule (MAdCAM) in vivo.

  本发明涉及硫醚单体和二聚体肽分子，它们在体内可抑制α4β7与粘膜地址细胞粘附分子（MAdCAM）的结合。
• Cyclic monomer and dimer peptides having integrin antagonist activity
  申请人：Protagonist Therapeutics, Inc.

  公开号：US10301371B2

  公开（公告）日：2019-05-28

  The invention relates to C to N cyclized (C-N cyclic) monomer and dimer peptide molecules, as well as peptide dimers which are connected by linker moieties at the N terminus and the C terminus of each peptide subunit, which inhibit binding of α4β7 to the mucosal addressin cell adhesion molecule (MAdCAM) in vivo, and show high selectivity against α4β1 binding.

  本发明涉及 C-N 环化（C-N cyclic）单体和二聚体肽分子，以及在每个肽亚基的 N 端和 C 端通过连接分子连接的肽二聚体，它们在体内可抑制 α4β7 与粘膜地址素细胞粘附分子（MAdCAM）的结合，并对α4β1 的结合具有高度选择性。
• Methods for synthesizing α4β7 peptide antagonists
  申请人：Protagonist Therapeutics, Inc.

  公开号：US10407468B2

  公开（公告）日：2019-09-10

  The present invention provides methods of making α4β7 peptide monomer and dimer antagonists. Methods of the present invention include solid phase and solution phase methods, as well as synthesis via condensation of smaller peptide fragments. Methods of the present invention further include methods directed to the synthesis of peptides comprising one or more penicillamine residues.

  本发明提供了制造α4β7 肽单体和二聚体拮抗剂的方法。本发明的方法包括固相和溶相方法，以及通过缩合较小的肽片段进行合成的方法。本发明的方法还包括合成包含一个或多个青霉胺残基的肽的方法。